1. Thailand Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Bangkok Dusit Medical Services Public Company Limited

Bangkok Dusit Medical Services Public Company Limited

BDUUY
Bangkok Dusit Medical Services Public Company LimitedUS flagOther OTC
23.41
USD
- -
- -
9.30BMarket Cap
Bangkok Dusit Medical Services Public Company Limited
BDUUY
(Other OTC)

Recent

price

23.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
77.89
99.14
117.71
130.93
144.74
162.25
175.34
185.74
198.77
210.18
171.34
187.39
231.4
253.84
271.5
280.66
280.9
Revenue per Share
7.53
12
20.32
16.2
19.09
20.71
21.66
26.38
23.61
39.43
18.16
19.98
31.73
36.14
40.24
39.89
39.16
Basic EPS, GAAP
10.47
6.68
6.22
1.42
6.19
16.85
8.96
-12.06
18.25
16.65
12.67
25.65
38.24
31.53
28.38
30.26
30.57
Free Cash Flow per Basic Share
2.79
2.71
4.4
7.2
8
9.2
14.4
12.79
14.37
17.64
11.93
32.06
19.99
26.03
27.99
29.99
13.99
Dividend per Share
21.46
29.24
43.23
52.35
60.24
71.65
79.06
92.61
100.77
120.17
122.55
111.66
124.79
134.88
145.71
155.01
165.23
Book Value per Share
46.84
58.12
68.99
78.61
77.87
93.88
101.96
119.89
138.02
170.94
182.65
173.51
188.24
200.64
211.71
225.79
236.39
Tangible Book Value per Share
305
365
386
387
387
387
387
387
389
394
397
397
397
397
397
397
397
Basic Weighted Avg Shares
23,734
36,234
45,478
50,615
56,054
62,834
67,904
71,933
77,373
82,723
68,074
74,451
91,934
100,853
107,867
111,507
111,602
Sales/Revenue/Turnover
14.27
16.08
17.12
15.08
15.99
15.65
14.61
14.33
15.24
14.57
12.52
15.07
18.47
18.73
18.96
18.08
17.71
Operating Margin (%)
2,123
2,707
2,951
3,244
3,716
4,387
4,803
5,168
5,386
5,752
6,413
6,321
5,950
5,848
6,132
6,848
7,026
Depreciation Expense
2,295
4,386
7,849
6,261
7,394
8,021
8,386
10,216
9,191
15,517
7,214
7,936
12,606
14,358
15,987
15,848
15,560
Net Income, GAAP
24.67
23.94
16.48
17.59
17.89
18.53
17.98
19.51
22.12
19.48
26.45
19.85
19.58
20.22
18.65
18.41
18.39
Effective Tax Rate (%)
9.67
12.1
17.26
12.37
13.19
12.76
12.35
14.2
11.88
18.76
10.6
10.66
13.71
14.24
14.82
14.21
13.94
Profit Margin (%)
-1,458
1,298
-2,287
-1,513
-1,160
-1,712
-5,282
977
-13,301
-2,938
18,792
8,539
7,183
5,112
1,646
-520
3,435
Working Capital
7,279
15,598
15,708
18,789
27,411
27,060
25,933
37,711
24,753
19,130
23,736
15,384
17,182
15,317
13,540
10,608
10,676
LT Debt
16,283
32,892
38,387
42,685
47,717
54,997
58,305
65,871
73,438
87,182
91,463
87,765
93,949
99,091
103,927
110,009
114,301
Total Equity
9.34
11.39
11.93
10.13
10.13
9.72
9.26
8.47
8.38
8.6
5.48
8.03
12.11
12.73
13.78
13.07
12.6
Return on Invested Capital (%)
14.39
20.2
24.59
16.31
15.47
14.7
13.92
15.5
12.03
20.04
9.79
11.09
17.3
18.73
20.3
19.13
18.49
Return on Capital (%)
36.45
50.92
57.31
33.9
33.94
31.41
28.74
30.73
24.48
35.87
15.03
17.06
26.84
27.83
28.68
26.53
24.33
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
8,131
6,879
3,345
LT Borrowings
3,000
3,000
3,000
LT Finance Leases
7,530
7,608
7,676
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15,892
15,892
15,892
Market Capitalization
417,036
305,934
264,953

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
22,132
23,109
25,273
Cash, Cash Equivalents & STI
7,050
7,242
8,122
Accounts Receivable, Net
11,119
11,638
12,313
Inventories
3,042
3,422
3,150
Total Current Liabilities
25,633
23,629
21,838
Payables & Accruals
15,955
15,236
17,325
ST Debt
8,131
6,879
3,345
Deferred Revenue
204
190
193

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.33%
3.84%
5.85%
Free Cash Flow
-43.39%
26.13%
6.62%
Net Income, GAAP
12.49%
18.65%
-0.87%
Sales/Revenue/Turnover
6.36%
10.58%
3.37%
Total Cash Common Dividend
22.66%
35.18%
7.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
26,609
25,704
28,151
27,404
107,867
2025
28,084
26,727
28,243
28,453
111,507
2026
28,179
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10.25
8.39
10.69
- -
40.24
2025
10.94
8.78
10.87
- -
39.89
2026
10.21
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
13.99
14
- -
27.99
2025
- -
- -
14
- -
29.99
2026
- -
- -
- -
- -
- -
Similar Companies
Concord Medical Services Holdings Limited (CCM)
Universal Health Services, Inc. (UHS)
Jack Nathan Medical Corp. (JNH.V)
Apollo Medical Holdings, Inc. (AMEH)
Skylight Health Group Inc. (SLHG)
Bumrungrad Hospital Public Company Limited (BH-R.BK)
Business
Bangkok Dusit Medical Services Public Company Limited (BDMS) operates Thailand's largest private healthcare group, providing comprehensive medical services through a network of over 47 hospitals and clinics across six main groups: Bangkok Hospital Group with 17 branches, Samitivej Hospital Group with five branches, BNH Hospital, Phyathai Hospital Group with five branches, Paolo Hospital Group with five branches, and Royal Hospital Group; the company also offers supporting services including medical laboratories, production and distribution of pharmaceutical products and medical equipment, pharmacies, asset management, accounting, technology and information services, training, insurance brokerage, wellness and preventive care through BDMS Wellness Clinic and BDMS Wellness Resort, rehabilitation, real estate, e-commerce, and specialized treatments in orthopedics, neurosurgery, hematology, cardiosurgery, oncology, plastic surgery, IVF, and gender reassignment. Founded in 1969 by Prasert Prasarttong-Osoth and headquartered at 2 Soi Soonvijai 7, New Phetchaburi Road, Bangkok 10310, Thailand, BDMS serves domestic Thai patients and international markets primarily from Asia-Pacific regions including Cambodia, China, and Myanmar, with operations spanning central Thailand, northern, northeastern, eastern, western, and southern regions. In recent developments, BDMS reported steady financial growth with Q2 2025 revenue up 4% and net profit rising 5%, driven by international patient volumes and upcountry expansion; Q1 2025 saw 7% profit growth from international patients; the company advances strategic initiatives as Asia-Pacific's robotic surgery hub, Thailand's first private minimally invasive heart surgery, Geno Life Services, proton therapy by 2029, a world-class rehabilitation hospital with Abilitylab partnership, and Medevac Center positioning, alongside recognition as a top human rights organization in 2024.